{"id":"NCT00864383","sponsor":"Global Alliance for TB Drug Development","briefTitle":"Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis","officialTitle":"A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening Regimen Comparing Two Months Moxifloxacin, Isoniazid, Rifampicin, Pyrazinamide Followed by Two Months Moxifloxacin, Isoniazid, Rifampicin Versus the Standard Regimen (Two Months Ethambutol, Isoniazid, Rifampicin, Pyrazinamide Followed by Four Months Isoniazid and Rifampicin) for the Treatment of Adults With Pulmonary Tuberculosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2013-10","completion":"2014-02","firstPosted":"2009-03-18","resultsPosted":"2015-05-25","lastUpdate":"2017-03-21"},"enrollment":1931,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Tuberculosis"],"interventions":[{"type":"DRUG","name":"Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin","otherNames":["Avelox","Avelon","Avalox","Myambutol","Nydrazid","Rifampin","Rifadin"]}],"arms":[{"label":"Regimen 1 - 2EHRZ/4HR (control regimen)","type":"PLACEBO_COMPARATOR"},{"label":"Regimen 2 - 2MHRZ/2MHR","type":"EXPERIMENTAL"},{"label":"Regimen 3 - 2EMRZ/2MR","type":"EXPERIMENTAL"}],"summary":"REMoxTB is a study for the \"Rapid Evaluation of Moxifloxacin in the treatment of sputum smear positive tuberculosis\". REMoxTB aims to find and evaluate new drugs and regimens that shorten the duration of tuberculosis therapy.\n\nThe purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two moxifloxacin-containing treatment combinations to determine whether substituting ethambutol with moxifloxacin in one combination, and/or substituting isoniazid with moxifloxacin in another combination, makes it possible to reduce the duration of treatment for TB.","primaryOutcome":{"measure":"Combined Failure of Bacteriological Cure and Relapse Within One Year of Completion of Therapy as Defined by Culture Using Solid Media (Lowenstein-Jensen - LJ).","timeFrame":"18 months (within one year of completion of therapy)","effectByArm":[{"arm":"Regimen 1 - 2EHRZ/4HR (Control Regimen)","deltaMin":43,"sd":null},{"arm":"Regimen 2 - 2MHRZ/2MHR","deltaMin":78,"sd":null},{"arm":"Regimen 3 - 2EMRZ/2MR","deltaMin":105,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":17},"locations":{"siteCount":47,"countries":["China","India","Kenya","Malaysia","Mexico","South Africa","Tanzania","Thailand","Zambia"]},"refs":{"pmids":["24461758","24429244","25196020","38468320","37986887","29779774","26847437"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":639},"commonTop":["Pyrexia","Weight Decreased","Vomiting","Dyspnoea","Chest Pain"]}}